A Phase 1 Study of MLN0128 and Bevacizumab in Patients With Recurrent Glioblastoma and Other Solid Tumors
Phase of Trial: Phase I
Latest Information Update: 16 Aug 2017
At a glance
- Drugs Sapanisertib (Primary) ; Bevacizumab
- Indications Endometrial cancer; Fallopian tube cancer; Glioblastoma; Ovarian cancer; Peritoneal cancer; Solid tumours
- Focus Adverse reactions
- 18 Apr 2017 Planned primary completion date changed from 1 Apr 2017 to 1 Oct 2016.
- 22 Nov 2016 Planned primary completion date changed from 1 Jun 2016 to 1 Apr 2017.
- 23 Oct 2016 Planned number of patients changed from 60 to 23.